tetano
Editor, Senior Moderator
Pharmaceuticals (Basel). 2015 Jun 18;8(2):351-65. doi: 10.3390/ph8020351.
[h=1]Effects of a Formula Containing Two Types of Prebiotics, Bifidogenic Growth Stimulator and Galacto-oligosaccharide, and Fermented Milk Products on Intestinal Microbiota and Antibody Response to Influenza Vaccine in Elderly Patients: A Randomized Controlled Trial.[/h]
[h=1]....[/h] Nagafuchi S[SUP]1[/SUP], Yamaji T[SUP]2[/SUP], Kawashima A[SUP]3[/SUP], Saito Y[SUP]4[/SUP], Takahashi T[SUP]5[/SUP], Yamamoto T[SUP]6[/SUP], Maruyama M[SUP]7[/SUP], Akatsu H[SUP]8,[/SUP][SUP]9,[/SUP][SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We investigated the effect of a formula containing two different prebiotics (bifidogenic growth stimulator and galacto-oligosaccharide) and fermented milk products on intestinal microbiota and antibody responses to an influenza vaccine in enterally fed elderly in-patients. Patients were administered either formula containing prebiotics and fermented milk products (group F: n = 12, 79.9 ? 9.5 years old) or standard formula (group C: n = 12, 80.7 ? 10.1 years old) via percutaneous endoscopic gastrostomy during a 14-week intervention period. Subjects were immunized with an influenza vaccine (A/H1N1, A/H3N2, and B) at week 4 of the intervention. Blood biochemical indices, intestinal bacteria populations and antibody titers were analyzed. Bifidobacterium counts increased significantly in group F compared with group C. The enhanced antibody titers against A/H1N1 were maintained in group F for a longer period compared with group C. The titers against A/H3N2 were unchanged between both groups, and those against B were significantly lower in group F than in group C, although few subjects had seroprotective titers against A/H3N2 and B. These results suggest that administration of the formula containing prebiotics and fermented milk products may maintain antibody titers for longer periods through the improvement of intestinal microbiota.
[h=4]KEYWORDS:[/h] Bifidobacterium; enterally fed patients; hemagglutination inhibition test; seroprotective rate
PMID: 26096655 [PubMed]
[h=1]Effects of a Formula Containing Two Types of Prebiotics, Bifidogenic Growth Stimulator and Galacto-oligosaccharide, and Fermented Milk Products on Intestinal Microbiota and Antibody Response to Influenza Vaccine in Elderly Patients: A Randomized Controlled Trial.[/h]
[h=1]....[/h] Nagafuchi S[SUP]1[/SUP], Yamaji T[SUP]2[/SUP], Kawashima A[SUP]3[/SUP], Saito Y[SUP]4[/SUP], Takahashi T[SUP]5[/SUP], Yamamoto T[SUP]6[/SUP], Maruyama M[SUP]7[/SUP], Akatsu H[SUP]8,[/SUP][SUP]9,[/SUP][SUP]10[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] We investigated the effect of a formula containing two different prebiotics (bifidogenic growth stimulator and galacto-oligosaccharide) and fermented milk products on intestinal microbiota and antibody responses to an influenza vaccine in enterally fed elderly in-patients. Patients were administered either formula containing prebiotics and fermented milk products (group F: n = 12, 79.9 ? 9.5 years old) or standard formula (group C: n = 12, 80.7 ? 10.1 years old) via percutaneous endoscopic gastrostomy during a 14-week intervention period. Subjects were immunized with an influenza vaccine (A/H1N1, A/H3N2, and B) at week 4 of the intervention. Blood biochemical indices, intestinal bacteria populations and antibody titers were analyzed. Bifidobacterium counts increased significantly in group F compared with group C. The enhanced antibody titers against A/H1N1 were maintained in group F for a longer period compared with group C. The titers against A/H3N2 were unchanged between both groups, and those against B were significantly lower in group F than in group C, although few subjects had seroprotective titers against A/H3N2 and B. These results suggest that administration of the formula containing prebiotics and fermented milk products may maintain antibody titers for longer periods through the improvement of intestinal microbiota.
[h=4]KEYWORDS:[/h] Bifidobacterium; enterally fed patients; hemagglutination inhibition test; seroprotective rate
PMID: 26096655 [PubMed]